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Although CEBPA double-mutated (CEBPA
DM) acute myeloid
leukemia is considered to be a favorable-risk disease, relapse
remains a major cause of treatment failure. Most CEBPADM
patients have a classic biallelic mutant combination with an N-terminal
mutation leading to production of p30 protein plus a C-terminal loss-of-
function in-frame indel mutation (CEBPAClassic-DM), but approximately one-
third of cases have one or more non-classic mutations, with diverse com-
binations reported, and there is little information on the consequences of
such mutants. We evaluated outcome in a cohort of 104 CEBPADM
patients, 79 CEBPAClassic-DM and 25 with non-classic mutants, and found
that the latter may have poorer survival (5-year overall survival 64% vs.
46%; P=0.05), particularly post relapse (41% vs. 0%; P=0.02). However,
for this analysis, all non-classic cases were grouped together, irrespective
of mutant combination. As CEBPADM cases have been reported to be
hypermethylated, we used methylation profiling to assess whether this
could segregate the different mutants. We developed a CEBPAClassic-DM
methylation signature from a preliminary cohort of 10 CEBPADM (includ-
ing 8 CEBPAClassic-DM) and 30 CEBPA wild-type (CEBPAWT) samples, and
independently validated the signature in 17 CEBPAClassic-DM cases.
Assessment of the signature in 16 CEBPADM cases with different non-clas-
sic mutant combinations showed that only 31% had a methylation pro-
file equivalent to CEBPAClassic-DM whereas for 69% the profile was either
intermediate between CEBPAClassic-DM and CEBPAWT or equivalent to CEB-
PAWT. These results suggest that CEBPADM cases with non-classic mutants
may be functionally different from those with CEBPAClassic-DM mutants,
and should not automatically be included in the same prognostic group.
(AML12 is registered under ISRCTN17833622 and AML15 under
ISRCTN17161961). 
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ABSTRACT
Introduction
The CEBPA gene encodes CCAAT/enhancer binding protein-α (C/EBPα), a basic
leucine zipper (bZIP) transcription factor that is essential for hematopoietic stem
cell regulation and myeloid development.1,2 The gene is mutated in approximately
8% of acute myeloid leukemia (AML) patients with intermediate-risk cytogenet-
ics, and presence of biallelic double mutations (CEBPADM) in the absence of an FLT3
internal tandem duplication (FLT3ITD) is associated with a favorable prognosis.3-9 In
the current risk-adapted therapy strategies for AML,10-12 these patients are classified
as good-risk and therefore not usually considered for consolidation of first remis-
sion by allogeneic transplantation.11,13 
Mutations occur throughout the single exon gene but predominate at the N and
C termini.14 N-terminal mutations are nearly always frameshift or nonsense muta-
tions causing increased translation from an internal ATG
start site and production of a truncated p30 protein that
retains the same reading-frame as the full-length p42 pro-
tein but lacks the first transactivation domain (TAD1). The
most common C-terminal mutations are in-frame indels in
the bZIP DNA binding domain (DBD) or leucine zipper
domain (LZD) that lead to loss of the ability to bind to
DNA or dimerize, classified here as C-terminal loss-of-
function (C-LOF). However, many other mutations have
also been reported, including missense mutations in the
DBD or LZD, missense mutations and in-frame indels in
the mid-region, and frameshift or nonsense mutations in
the mid-region or C-terminus. Some also present as
homozygous alterations due to chromosome 19 uni-
parental disomy.15,16 The most common combination of
mutations is an N-terminal frameshift on one allele plus a
C-terminal in-frame indel on the other allele that together
are predicted to lead to complete loss of normal p42
C/EBPα activity,14 hereafter called the classic CEBPADM
combination (CEBPAClassic-DM). This combination was identi-
fied in 204 of 305 CEBPADM cases (67%) with defined
mutants reported in six studies containing 20 or more
CEBPADM cases.3,6,8,17-19 The remaining 101 cases had multi-
ple different mutant combinations with diverse conse-
quences: 54 (18% of total CEBPADM) would be predicted to
produce just p30 due to the presence of a mid-region or C-
terminal truncation, 12 (4%) would only produce a classic
C-LOF protein, 19 (6%) p30 plus a C-terminal missense
mutant, 5 (2%) just a C-missense mutant, and 11 (4%)
other mutant combinations.
Understanding the consequence of the different types
of CEBPADM mutants is needed as this may impact on
clinical outcome, but there is limited information avail-
able on the specific mutations. CEBPADM cases have gene
expression profiles that are significantly different from
single-mutated (CEBPASM) and wild-type (CEBPAWT)
cases.3,7 However, recent data suggest that CEBPADM
cases with non-classic combinations may not always
cluster with other CEBPADM cases,7,20 with 3 of 7 such
cases classified as negative for the CEBPADM expression
profile in one report.20 Furthermore, genotype stratifica-
tion according to expression profiling may be confound-
ed by CEBPAWT cases with completely silenced CEBPA
expression (CEBPASIL) due to methylation of the CEBPA
promoter as these cases cluster together with CEBPADM
cases.21 CEBPADM cases also form distinct epigenetic clus-
ters with a markedly hypermethylated profile.22,23 But
although CEBPASIL cases also have a hypermethylated
profile, this segregates from the CEBPADM cluster and,
interestingly, they appear to be associated with a biolog-
ically distinct subtype of AML with a poor progno-
sis.21,22,24 Potential methylation differences according to
the underlying combination of CEBPA mutants, howev-
er, have not been reported. 
In order to investigate potential differences between
CEBPADM mutant combinations, we evaluated clinical out-
come in 104 CEBPADM cases (79 CEBPAClassic-DM and 25 with
non-classic mutants) and observed that the non-classic
cases may have a lower overall survival (OS). However,
the number of cases was relatively small and all cases with
a non-classic mutant were included in this group, irrespec-
tive of the mutant type. We therefore investigated
whether methylation profiling of samples from double-
mutated patients could assist in segregating the different
mutant combinations. 
Methods
Patient cohorts
The patients investigated were younger adults entered into the
UK MRC AML10, AML12 and AML15 trials. Informed patient
consent was obtained in accordance with the Declaration of
Helsinki, and ethical approval for tissue use from the Wales
Research Ethics Committee 3. Clinical outcome was evaluated in
104 CEBPADM patients, all under 60 years of age, and methylation
profiling was performed on 135 patients: 132 (98%) of them under
60 years of age (Online Supplementary Figure S1). Selected tests
were performed on a further 82 samples with specific cytogenetic
and molecular abnormalities.
Therapy, clinical end points and statistical methods
Details of clinical protocols, end points and statistical methods
are defined in the Online Supplementary Appendix.
Methylation arrays and data processing
DNA was bisulfite-converted using the EZ DNA Methylation-
Gold Kit (Zymo Research, California, USA) and random samples
checked by methylation-specific PCR to ensure efficient conver-
sion (see the Online Supplementary Appendix). Methylation profil-
ing was performed using the Illumina Infinium
HumanMethylation27 (n=40, cohort 1) and
HumanMethylation450 (n=95, cohort 2) BeadChip arrays
(Illumina Inc., California, USA). Details of data processing are
given in the Online Supplementary Appendix.Derived β values were
expressed as the percentage methylation at a given CpG probe.
Selected CpG sites were further analyzed using pyrosequencing
assays (see the Online Supplementary Appendix). 
Unsupervised analysis of patient methylation profiles
In a given sample, probes were defined as methylated if the β
value was more than 0.3, unmethylated if 0.3 or under.25 Samples
were clustered based on their β values at probes displaying signif-
icant variation (variable probes), as previously defined.25,26 They
were defined as variable if methylated in 1 sample or more plus
unmethylated in 1 sample or more. CpG islands (CGIs) were
located as previously defined;27 their methylation levels were
derived by calculating the mean β value of probes at these loca-
tions. Hierarchical clustering was performed using the Euclidian
distance of β values and Ward algorithm in R.
Derivation and analysis of CEBPA signature
A methylation signature of CEBPA genotype was derived from
variably methylated CpGs in cohort 1. Signature CpGs were
selected as the top 25 ranked probes based on the mean rank of 
P-values of Wilcoxon tests and the absolute median difference in
β value between CEBPAClassic-DM and CEBPAWT samples. Probes were
included in the analysis if  more than 90% of samples and 2 or
more  CEBPAClassic-DM and 2 or more  CEBPAWT samples had observ-
able data. Methylation signatures of CEBPAClassic-DM and CEBPAWT
samples were then defined as the median β values observed at
these 25 probes. Samples were scored relative to these signatures
by calculating the Euclidian distance between the signatures and
their profiles at signature probes.
Mutant CEBPA level and confirmation of biallelic 
status
Mutant CEBPA level was quantified as previously described6 or
approximated from the sequence chromatogram (average height
of ≥5 peaks). Monoallelic/biallelic status was investigated by
sequencing clones derived from full-length CEBPA amplicons as
previously described.6
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Results
Clinical outcome in CEBPADM cases according 
to mutant type
Of the 104 CEBPADM cases evaluated, 79 had classic and
25 had non-classic mutants (Table 1 and Online
Supplementary Table S1). The latter included 4 patients pre-
dicted to produce p30 plus a C-terminal missense mutant,
8 with combinations predicted to produce just p30, and 13
with different combinations predicted to produce just a C-
LOF protein. There was no difference in the baseline char-
acteristics between the classic and non-classic cases,
including white cell count, sex, World Health
Organization (WHO) performance status, and AML type
(de novo or secondary), although the non-classic cases were
older (median 35 vs. 47 years; P=0.001) (Online
Supplementary Table S2). All classic cases had intermediate-
risk cytogenetics compared to 89% of the non-classic
cases (P=0.05). There was no significant difference in the
incidence of FLT3ITD, NPM1, IDH1, WT1, TET2 andGATA2
mutations between the groups, although the non-classic
cases had more IDH2mutations (1% vs. 20%, P=0.003; all
IDH2R140Q) and DNMT3Amutations (3% vs. 16%, P=0.03).
Median follow up was 9.5 years (range: 0.1-22 years).
Neither the proportion of transplanted patients, the type
of transplant, nor the stage of transplantation differed
between the groups (Online Supplementary Table S2).
CEBPAClassic-DM cases had a slightly higher but statistically
non-significantly different complete remission (CR) rate to
non-classic cases (95% vs. 88%, P=0.2) (Table 2). In uni-
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Table 1. CEBPA genotype of investigated cohorts. 
CEBPA genotype* Number Predicted functional consequence
Clinical cohort CEBPAClassic-DM 79 p30 + C-LOF
(n=104)
Non-classic CEBPADM
Classic N + C-missense 4 p30 + C-LOF
Classic N + mid-frameshift 5 p30
Classic N + C-frameshift 2 p30
Homozygous classic N 1 p30
Homozygous classic C 4 C-LOF
Homozygous C-missense 3 C-LOF
Classic C + C-frameshift 4 C-LOF
Classic C + C-missense 1 C-LOF
Mid-frameshift + C-missense 1 C-LOF
Methylation CEBPAClassic-DM 8 p30 + C-LOF
Cohort 1 (n=40) Non-classic CEBPADM 
Classic C + C-frameshift 1 C-LOF
Homozygous C-missense 1 C-LOF
CEBPAWT 30 WT
Methylation CEBPAClassic-DM 17 p30 + C-LOF
Cohort 2 (n=95) Non-classic CEBPADM 
Classic N + C-missense 3 p30 + C-LOF
Classic N + mid-frameshift 5 p30
Classic N + C-frameshift 1 p30
Homozygous classic C 2 C-LOF
Homozygous C-missense 2 C-LOF
Classic C + C-missense 1 C-LOF
CEBPASM
Classic N 9 p30 + WT
Classic C 5 C-LOF + WT
Mid-indel     3 UNK + WT
Mid-frameshift 9 Null**+ WT
Mid-missense 5 UNK + WT
C-frameshift 2 Null** + WT
C-missense 5 C-LOF + WT
CEBPAWT 26 WT
*Details of the specific mutations are given in Online Supplementary Table S1.**Mid-region or C-terminal mutants with a truncating frameshift or nonsense mutation. C: C-ter-
minal mutation; C-LOF: C-terminal loss-of-function; DM: double mutant; indel: in-frame insertion and/or deletion; N: N-terminal mutation; SM: single mutant; UNK: unknown; WT:
wild-type.
variate analysis, there was no significant difference in
relapse-free survival or relapse rate (RR). However, there
was a trend towards a lower OS in the non-classic cases
(64% vs. 46% at 5 years, P=0.05) (Figure 1A), which was
largely due to the worse outcome post-relapse in the non-
classic cases. The proportion of relapsing patients who
achieved a second remission did not differ between the
groups (61% vs. 55%), but 5-year survival post relapse
was 41% versus 0% (P=0.02) (Figure 1B), and 59% versus
0% from second remission (P=0.004) (Figure 1C). The sur-
vival differences were not, however, statistically different
in multivariate analysis (Table 2), but this is not surprising
given the small group sizes. Although the significantly
higher proportion of DNMT3A-mutated cases in the non-
classic group could have contributed to their worse out-
come, as both these mutations and FLT3ITD adversely
impact on the favorable outcome associated with 
CEBPADM AML,6,28 the trend towards a lower OS in the
non-classic cases was still present when patients with
these mutations were excluded (70% vs. 53%; Hazard
Ratio 1.95, 95% confidence intervals 0.95-4.01; P=0.08)
(Figure 1D). 
Development of a CEBPAClassic-DM methylation 
signature
The clinical evaluation grouped all non-classic cases
together in order to obtain an adequate number of
patients for analysis, but this cohort, therefore, included
patients with many mutant combinations predicted to
have differing functional consequences. In order to
explore potential methods for discriminating between
these combinations, we investigated the impact of mutant
type on methylation profiles. A preliminary cohort of
samples from 40 normal karyotype (NK) FLT3WTNPM1WT
patients were investigated using the Illumina Infinium
HumanMethylation27 array: 10 were CEBPADM and 30
were CEBPAWT (Methylation cohort 1) (Table 1), approxi-
mating the relative proportions of such cases in NK
FLT3WTNPM1WT patients in our earlier study.6 The array
data were validated by pyrosequencing assays at four dif-
ferentially methylated CpG sites (Online Supplementary
Figure S2). Most CpG sites analyzed showed little varia-
tion in methylation levels across the whole cohort, but
unsupervised cluster analysis according to levels of the
most variably methylated probes revealed two main clus-
ters. All 10 CEBPADM samples, including two non-classic
cases, fell in the cluster of 16 samples with significantly
higher levels of mean CGI methylation (Figure 2A), and
the mean level of CGI methylation was significantly dif-
ferent between CEBPAClassic-DM and CEBPAWT samples
(Figure 2B). 
A supervised approach was then used to create
CEBPAClassic-DM and CEBPAWT methylation signatures based
on the 25 most differentially methylated sites between the
CEBPAClassic-DM and CEBPAWT samples (Figure 2C and Online
Supplementary Table S3). Two distance scores were calcu-
lated for each sample based on the Euclidian distance
between their methylation levels at these signature probes
and the median profile of the CEBPAClassic-DM and CEBPAWT
samples. This confirmed that, when assessed according to
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Figure 1.Clinical outcome in CEBPADM patients according to mutant combination. (A) Overall survival in the total cohort of 104 CEBPADM patients. (B) Survival post
relapse in the 39 patients who relapsed. (C) Survival from second remission in the 23 relapsed patients who achieved a second remission. (D) Overall survival in the
total cohort excluding patients with FLT3ITD and DNMT3A mutations. 
A B
C D
P=0.02
P=0.08
P=0.004
P=0.05
their distance scores, the CEBPAClassic-DM samples formed a
distinct group that were clearly separate from the 
CEBPAWT samples (Figure 3A). 
The CEBPAClassic-DM methylation signature was validated
with samples from a further 17 CEBPAClassic-DM and 26 
CEBPAWT cases (Methylation cohort 2) (Table 1) using the
HumanMethylation450 array. Sixteen of the 17
CEBPAClassic-DM cases (94%) fell in the same cluster in unsu-
pervised analysis, with a relatively more hypermethylated
profile, and all CEBPAWT cases fell in the hypomethylated
cluster (Online Supplementary Figure S3). Using supervised
analysis according to the derived CEBPAClassic-DM and 
CEBPAWT signatures, the same 16 CEBPADM cases had a
methylation profile that was closest to the CEBPAClassic-DM
signature with a wide difference between the two signa-
tures (Figures 3B and 4), indicating that their profile was
equivalent to the CEBPAClassic-DM cases in cohort 1. Further
analysis of the one CEBPAClassic-DM case that fell closer to the
CEBPAWT group indicated that the mutations were biallelic
but only approximately half of the cells in the sample car-
ried mutations; mean mutant level was 28% for the pair,
which was the lowest mean level of all 25 
CEBPAClassic-DM cases (median 44%; range: 28-50%). The
methylation profile of this case could, therefore, have
been affected by the presence of a significant proportion
of non-leukemic cells and it was excluded from further
analyses. Using the distance scores (mean±2SD) for
CEBPAClassic-DM cases in cohort 1, tests showed that these
scores classified CEBPAClassic-DM and CEBPAWT genotypes in
the second cohort with 95% accuracy, 88% sensitivity,
and 100% specificity. The distance scores of the 24
CEBPAClassic-DM cases from the combined cohorts were then
used to define a CEBPAClassic-DM quadrant that segregated all
CEBPAClassic-DM cases from CEBPAWT cases (Figure 3C).
Investigation of the CEBPAClassic-DM methylation signature
in other good-risk patients
In order to examine whether the CEBPAClassic-DM methyla-
tion signature could simply reflect ‘good-risk’ disease or
be due to a lack of C/EBPα expression, methylation levels
at three differentially methylated CpG sites from the sig-
nature were quantified by pyrosequencing using samples
from 21 patients with inv(16) and 19 with t(8;21), both
associated with down-regulated C/EBPα expression,29-31
and 42 with NPM1MUTFLT3WT.  KHNYN and VAMP5 were
more hypermethylated in the CEBPAClassic-DM signature,
while LY9 was more hypomethylated. Each subgroup dif-
fered significantly from the 24 CEBPAClassic-DM cases at two
of the three sites (Online Supplementary Figure S4). A com-
posite methylation score was calculated for each sample;
it was statistically significantly different from the
CEBPAClassic-DM cases for all three subgroups (Figure 5), indi-
cating that the methylation profile was a distinct feature
of the mutant proteins that lead to total loss of normal
C/EBPα function rather than absence of C/EBPα per se.
Investigation of non-classic CEBPADM and CEBPASM
mutants
Having established that CEBPAClassic-DM cases have a
methylation profile that is distinct from CEBPAWT cases,
profiles of 14 CEBPADM cases with a variety of different
non-classic combinations were investigated using the
HumanMethylation450 array (Methylation cohort 2)
(Table 1). On unsupervised analysis, 9 (64%) were hyper-
methylated and 5 (36%) hypomethylated (Online
Supplementary Figure S3). To assess their impact on the
CEBPA methylation signatures, these 14 cases and the 2
non-classic cases from the initial cohort were considered
according to the predicted functional consequence of the
combination. 
Six cases were predicted to produce just p30 protein,
with a classic N plus null mutant (mid-region or C-termi-
nal frameshift/nonsense) combination. Only 1 fulfilled the
CEBPAClassic-DM criteria; 4 fell outside this quadrant but were
still distinct from CEBPAWT cases, and 1 grouped with the
CEBPAWT cases (Figure 6A). Three cases were predicted to
just give rise to classic C-LOF proteins without p30 (2
homozygous classic C, 1 compound heterozygous with a
classic C plus C-frameshift combination). Two fulfilled the
CEBPAClassic-DM criteria and 1 was intermediate between
CEBPAClassic-DM and CEBPAWT. The 7 cases with missense
mutations were also highly variable. Three had a classic N
plus C-missense combination; none fulfilled the
CEBPAClassic-DM criteria, 2 were intermediate between the
signatures, and 1 grouped with CEBPAWT cases. Mutant
levels were indicative of 80% or more mutated cells in all
3 cases; 2 were biallelic by cloning but no full-length
amplicons could be obtained in 1 case. Similarly, only 1 of
the 3 homozygous C-missense cases fell in the 
CEBPAClassic-DM quadrant, the other 2 were equivalent to
CEBPAWT cases. The remaining case was compound het-
erozygous with a classic C and C-missense combination,
and this did fulfil the CEBPAClassic-DM criteria. 
These results suggest that the functional consequence of
double-mutated cases producing at least 1 non-classic
mutant protein can be highly variable and difficult to pre-
dict. Of note, when outcome was assessed in the non-clas-
sic cases according to their methylation profile, there was
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Table 2. Outcome according to CEBPADM mutant combination.
Outcome Classic Non-classic CEBPAClassic-DM vs. non-classic CEBPADM
CEBPADM CEBPADM OR or HR (95% CI), P
(n=79) (n=25) Univariate  Multivariate*
CR 95% 88%** 3.20 (0.53-19.47), P=0.2 Not evaluable***
5-year OS 64% 46% 1.84 (1.01-3.37), P=0.05 1.44 (0.74-2.79), P=0.3
5-year RFS 49% 45% 1.15 (0.61-2.16), P=0.7 1.03 (0.52-2.06), P=0.9
5-year RR 41% 47% 1.32 (0.66-2.66), P=0.4 1.09 (0.47-2.55), P=0.8
*Adjusted for age, white blood cell count, World Health Organization performance status, type of leukemia, sex, FLT3 and DNMT3A genotype. **Remission status was missing
for one patient. ***Insufficient events for analysis. P: P-value; n: number; CI: confidence intervals; CR: complete remission; DM: double mutant; HR: hazard ratio; OR: odds ratio;
OS: overall survival; RFS: relapse-free survival; RR: relapse rate.
a suggestion that those that fulfilled the CEBPAClassic-DM
methylation criteria were less likely to relapse, with only
1 of 4 cases (25%) relapsing compared to 7 of 10 cases
(70%) that fell outside the CEBPAClassic-DM quadrant (5-year
RR 25% vs. 54%, respectively). These numbers were too
small for meaningful statistical analysis, and the results do
not necessarily indicate a causal link between the methy-
lation pattern and outcome. They do suggest, however,
that the methylation pattern could be a useful biomarker,
and thereby act as a surrogate for response and selection
of therapy. 
Methylation cohort 2 also included 38 CEBPASM cases
with a wide range of classic and non-classic mutants
(Table 1). On unsupervised analysis, 31 (82%) were in the
hypomethylated cluster, with no apparent segregation
between the CEBPASM and CEBPAWT cases (Online
D. El-Sharkawi et al.
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Figure 2. Methylation profile of the preliminary cohort of 40 samples.
(A) Unsupervised cluster analysis of the cohort. Each column repre-
sents one patient. Genotype is given in the upper panel. Samples were
clustered based on their methylation levels at 7679 variable probes,
and the heatmap in the middle panel shows the variable CpG probes
located within CpG islands (CGIs). The latter were used to calculate the
mean % CpG methylation shown in the lower panel; red and blue bars
indicate a predominantly hyper- or hypo-methylated profile, respective-
ly. (B) The mean level CGI methylation for CEBPAWT and CEBPAClassic-DM
samples. CGI methylation levels were calculated from all autosomal
CGI probes. ***P<0.001 (Wilcoxon test). (C) Supervised cluster analy-
sis showing the derived CEBPAClassic-DM signature (left) and the CEBPAWT
signature (right). Samples are ordered according to their level of simi-
larity to the CEBPAClassic-DM signature using Euclidian distance. (Bottom)
Distance scores indicating the distance from the CEBPAClassic-DM (green
circles) and CEBPAWT (white circles) signatures; the lower the y-axis
value, the more closely the sample matches that particular signature. 
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Supplementary Figure S3). On supervised analysis, all
except 2 cases were equivalent to CEBPAWT cases, with no
obvious grouping according to the type of mutant (Figures
4 and 6B). The remaining 2 cases fell in or close to the
CEBPAClassic-DM quadrant; both had a classic C mutation. It is
possible that the CEBPAWT allele had been silenced in these
cases, but RNA samples were not available to check this.
Discussion
Molecular genotyping is increasingly used to risk strati-
fy patients with AML, but clinical application of this infor-
mation needs to be accurate and robust for optimal patient
therapy. This is particularly important for good-risk
patients such as those with biallelic CEBPA mutations,
where the current recommendation is not to proceed to
transplantation in first remission, as for some patients this
could lead to undertreatment. Identifying those who are at
greater risk of relapse and poorer survival may, therefore,
guide patient management. Very limited information is
available on the impact of the different CEBPAmutations,
with all CEBPADM cases currently being classified as good-
risk, irrespective of the underlying mutant. However,
mutations identified in approximately one-third of CEB-
PADM patients do not conform to the classic combination of
N-terminal frameshift or nonsense mutation plus C-termi-
nal in-frame indel. As many of the other mutations are
unique and of unknown functional consequence, deter-
mining their significance is challenging, particularly in
view of the multiple functions attributed to C/EBPα.1,2
Although we had access to a database of 2162 patients
with known CEBPA genotype and available clinical data
from three consecutive UK MRC trials of younger adult
patients with AML, 67% with intermediate-risk cytoge-
netics, we were still able to evaluate long-term outcome in
a cohort of only 79 CEBPAClassic-DM cases and 25 CEBPADM
cases with at least one non-classic mutant. The results
suggested that the non-classic cases may have a poorer
outcome; in particular, none of these cases survived after
relapse. These results may be influenced by differences in
the coincident mutations in the two groups. The majority
of recurrent mutations with known prognostic signifi-
cance in AML are uncommon in CEBPADM cases,32 and for
many of them their impact in this subgroup is, therefore,
not well defined. Both FLT3ITD and DNMT3A mutations
adversely impact on the favorable outcome of CEBPADM
AML.6,28 But even when patients with these mutations
were excluded from the analysis, OS for the non-classic
cases was still worse. The incidence of GATA2 mutations
was non-significantly lower in the non-classic cases, but
although one study reported that they are associated with
better OS,33 most studies, including our own, observed no
difference.34,35 There was a non-significantly higher inci-
dence of TET2mutations in the non-classic cases, but their
impact is unclear, with only one study reported specifical-
ly for CEBPADM AML that showed a worse OS but not
event-free survival in TET2MUT cases.33 Clearly, many more
cases would need to be analyzed in order to take into
account coincident mutations other than FLT3ITD and
DNMT3A mutations.
A wide range of non-classic mutations was observed
and, for the outcome analysis, sufficient patient numbers
could only be obtained by grouping all the non-classic
patients together, which precluded evaluation of specific
mutant combinations. We, therefore, sought alternative
methods of assessment and, as CEBPADM patients have a
distinct hypermethylated profile,22,23 investigated whether
genome-wide methylation profiling could provide infor-
mation on the more broad-spectrum functional conse-
quence of different mutants. We confirmed the relatively
hypermethylated profile associated with a CEBPADM geno-
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Figure 3. Analysis of the methylation profiles of the samples according to their
distances from the derived CEBPAClassic-DM and CEBPAWT methylation signatures.
Difference between the distance scores (CEBPAClassic-DM - CEBPAWT) compared with
the distance from the CEBPAClassic-DM (MUT) signature of (A) the preliminary cohort
and (B) the CEBPAClassic-DM and CEBPAWT cases in the follow-up cohort. (C) Criteria
derived for CEBPAClassic-DM using mean±2Standard Deviation (SD) of the distance
scores of all 24 CEBPAClassic-DM cases.
A
B
C
type in a preliminary cohort and then derived methylation
signatures for CEBPAClassic-DM and CEBPAWT cases using the
25 most differentially methylated CpG sites. These were
validated in an independent cohort of samples, with 16 of
the 17 CEBPAClassic-DM cases studied clearly separating from
the CEBPAWT cases. The remaining case contained a signif-
icant proportion of non-mutated cells, which provided
indirect evidence that the signatures reflected CEBPA
genotype. The signatures were a distinct feature of mutant
C/EBPα and could not simply be attributed to a lack of
C/EBPα, as they were not replicated in samples from
patients with core-binding factor leukemias that are asso-
ciated with downregulation of CEBPA expression.
Presence of at least a minimal level of C/EBPα activity is
thought to be necessary for the development of leukemia
as Cebpa-/- mice with totally absent C/EBPα accumulate
immature myeloid progenitors but do not develop
AML,36,37 and AML patients have not been reported with
mutations leading to complete absence of C/EBPα. These
results, therefore, suggest that it is the functionally aber-
rant C/EBPα protein that underlies the hypermethylated
profile detected in the CEBPADM cases.
The CEBPAClassic-DM cases provided a framework for
assessing the methylation profiles of mutant combina-
tions with at least one non-classic mutant. Only 31% had
a methylation profile equivalent to CEBPAClassic-DM, 25%
were equivalent to CEBPAWT, and 44% were intermediate
between the two. Similar heterogeneity has been reported
for gene expression profiles of non-classic cases, with 3 of
7 such cases segregating from cases with classical
mutants.20 This variability is not surprising considering the
diversity of the mutant combinations. Although the p30
isoform is thought to play an important role in allowing
commitment of the leukemic stem cell to the myeloid lin-
eage,38 the mechanism by which it promotes AML is not
clearly defined. It has a lower affinity for some C/EBP sites
than p42 and induces multiple genes that are not affected
by p42,39-41 and this may have influenced the methylation
profile. Knock/in mice expressing just N-terminal mutant
developed leukemia but more slowly than the N+C com-
bination.38,42 This presumably reflects the additional influ-
ence of an aberrant C-terminally mutated protein that
might not bind to DNA but can still bind to other C/EBP
interacting proteins, such as PU.1 and the SWI/SNF com-
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Figure 4. Analysis of the follow-up cohort of 95 samples. Supervised analysis according to the CEBPAClassic-DM and CEBPAWT methylation signatures. Patient CEBPA
genotype is given above the heatmap. (Bottom) Distance scores indicating the distance from the CEBPAClassic-DM (green circles) and CEBPAWT (white circles) signatures;
the lower the y-axis value, the more closely the sample matches that particular signature. 
Figure 5. Methylation levels in other good-risk groups compared to the
CEBPAClassic-DM cases. A composite methylation score was calculated by summing
the difference between the % methylation for samples and the median for the
24 CEBPAClassic-DM cases (excluding the outlier) for three differentially methylated
CpG sites: KHNYN, VAMP5 and LY9. Mean values±95% confidence intervals are
shown. The CEBPAClassic-DM and CEBPAWT results were β values from the arrays;
results for the three comparative groups were obtained by pyrosequencing.
Significance refers to difference from the CEBPAClassic-DM group. ***P≤0.001. 
plex. Classic C-terminal mutants are associated with
hyperproliferation due to loss of cell-cycle regulation and
a block in myeloid differentiation.43 Although knock/in
mice with classic C mutant alone do develop leukemia, it
is with slower latency than the N+C and mutant N mice.42
Since these mutants may still bind and potentially
sequester other interacting factors, it has been suggested
that this could limit the ability of other C/EBPs to rescue
the effect of the aberrant C/EBPα,2 as shown for C/EBPβ
in the C/EBPα-deficient situation.44,45 This more global cel-
lular impact of the C-terminal mutants may have a greater
consequence for signaling events downstream of C/EBPα,
which may, therefore, be reflected in the methylation pro-
file.
The methylation profiles did not group according to the
predicted functional consequence of the mutant, whether
N- or C-terminally mutated. For example, considerable
variability was observed for the cases with a C-missense
mutation. Of the three classic N plus C-missense combi-
nations assayed, 1 case had a methylation profile equiva-
lent to CEBPAWT and 2 cases had intermediate profiles.
Two homozygous C-missense cases grouped with 
CEBPAWT cases, whereas another homozygous C-mis-
sense case grouped with the CEBPAClassic-DM cases. In the 51
cases documented with C-missense mutations in the
COSMIC database (http://cancer.sanger.ac.uk/cosmic), most
mutations are unique, reported in 1 (n=27, 53%) or 2 (n=9,
18%) patients, and only two residues (R297 and R300) are
recorded as being variably mutated in 5 patients. Critical
amino acids at the bZIP/DNA interface have been identi-
fied from the C/EBPα crystal structure, but many addi-
tional hydrogen bonds and van der Waals contacts are
implicated in the stabilization of these interactions.46 Thus,
predicting the functional consequence of these mutants is
difficult. 
From a clinical perspective, risk management requires
evaluation of all the available information, and the data
presented here suggest that CEBPADM patients with a non-
classic mutation should not automatically be included in
the same favorable-risk prognostic group as CEBPAClassic-DM
cases; it might be appropriate to consider them for allo-
geneic transplantation in first remission. Ultimately, this
can only be proven by analysis of clinical trial outcomes
and, with the increasing availability of large data sets
using targeted next-generation sequencing panels, such
analysis may be feasible in the future. This will also pro-
mote a better understanding of the mutational back-
ground of classic and non-classic CEBPADM cases and
whether there are differences that impact on their progno-
sis. Our studies also raise the possibility that methylation
profiling may identify those non-classic cases that behave
in a similar manner to classic mutants; although we can-
not directly attribute a causal link between the methyla-
tion pattern and chemosensitivity, and further studies are
required before this is introduced into clinical practice. 
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